North America Diabetes Care Devices Market Size
| Study Period | 2019- 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 27.52 Billion |
| Market Size (2029) | USD 37.19 Billion |
| CAGR (2024 - 2029) | 6.21 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
North America Diabetes Care Devices Market Analysis
The North America Diabetes Care Devices Market size is estimated at USD 27.52 billion in 2024, and is expected to reach USD 37.19 billion by 2029, growing at a CAGR of 6.21% during the forecast period (2024-2029).
The PAHO Panorama of Diabetes report highlights the alarming increase in diabetes cases in the Americas. The projected number of individuals affected by diabetes is expected to rise from 62 million in 2022 to 109 million by 2040 if current patterns persist. This emphasizes the urgent need for increased awareness, prevention, and management strategies to address this growing public health challenge. Further, the report emphasizes the importance of early detection and diagnosis, as many individuals may be living with diabetes without even realizing it. This lack of awareness can delay necessary treatment and increase the risk of complications. Therefore, efforts to improve screening and testing for diabetes are crucial to identify and support those who are affected.
The North American region has witnessed an astounding increase in the prevalence of diabetes, in recent years. In developed countries, such as the United States and Canada, the rate of diabetes is at an all-time high, mainly due to lifestyle changes. Diabetes is associated with many health complications. Comparing the population with and without diabetes, those with diabetes have a 300% increased risk of being hospitalized and thus incur more healthcare expenses compared to non-diabetic people.
Patients with Type 2 diabetes require many corrections throughout the day to maintain nominal blood glucose levels, such as the administration of additional insulin or ingestion of additional carbohydrates. Furthermore, patients attempting to control their blood glucose levels tightly to prevent the long-term complications associated with fluctuations in blood glucose levels are at greater risk for overcorrection and the resultant hypoglycemia. Achieving nominal results can be very difficult without multiple daily injections of insulin or insulin pump therapy. This is driving the demand for diabetes care devices in North America, thereby driving the market in focus during the forecast period.
North America Diabetes Care Devices Market Trends
Monitoring Devices is Having the Highest Market Share in Current Year
Monitoring devices are garnering widespread adoption due to the availability of reimbursement options for glucose meters. Glucose meter devices must be replaced within six to eight months and are very expensive. As a result, most people prefer selecting health insurance plans that cover almost 80% of the total expenditure on healthcare devices.
Such schemes cover the cost of diabetes testing supplies, blood glucose test strips, and blood glucose meters. For example, Medicare, the federal health insurance program in the United States, covers approximately 80% of the cost of BGM devices for diabetic people.
The usage of CGM devices is on the rise in North America because of their advancement in technology and their ability to empower people with diabetes to make more informed decisions about their health. This is driving the demand for diabetes care devices in North America, thereby driving the market in focus during the forecast period.
The United States is Expected to Dominate the North America Diabetes Care Devices Market.
The United States is expected to grow tremendously during the forecast period, owing to factors such as the high prevalence of obesity and increasing awareness regarding diabetes care in the region.
According to the American Diabetes Association, 1.4 million Americans are thought to receive a diabetes diagnosis each year. In Canada and other North American nations, diabetes is one of the main killers. The disease's rising incidence, prevalence, and progressive nature have motivated the development of novel medications to give diabetic patients more treatment options. Non-insulin medications, which serve as first-line therapies for people with type-2 diabetes, currently account for more than half of sales in the anti-diabetic market.
Innovations in insulin pump devices in the United States are driving the market. Medtronic received FDA clearance for its new extended-wear infusion set, designed to last more than twice as long as existing infusion sets that connect traditional tubed pumps to the body for insulin delivery.
That means it can be worn on the body for up to 7 days, compared to existing sets that must be changed every 2 or 3 days. In the United States, there are innovations from start-up companies with approximately USD 2.9 billion in funding in the diabetes industry, like Glooko, OneDrop, Verily, Vacate, Insulet, Noom, Bigfoot Biomedical, Virta Health, Diabeloop, Orgenesis, etc. Thus, owing to the above factors, it is expected to drive market growth over the forecast period.
North America Diabetes Care Devices Industry Overview
A select few big players control the market. Abbott's new FreeStyle Libre Flash glucose monitoring system was approved, which is the first continuous blood sugar monitor for people with diabetes that does not need backup finger prick tests. Innovations in test strips are increasing and are under development. For example, the new test strip includes features such as underfill detection and provides the user with the ability to reapply blood when the test strip is underfilled ("second chance" sampling). Dexcom acquired TypeZero Technologies, paving the way for automated insulin delivery. The acquisition has sent Dexcom ahead in the race to create an artificial pancreas system rather than simply offering a continuous glucose monitoring device.
North America Diabetes Care Devices Market Leaders
-
Dexcom
-
Medtronic
-
F. Hoffmann-La Roche AG
-
Novo Nordisk
-
Becton, Dickinson and Company
*Disclaimer: Major Players sorted in no particular order
North America Diabetes Care Devices Market News
- April 2023: Abbott has announced the clearance of its FreeStyle Libre 3 integrated continuous glucose monitoring (iCGM) system by the U.S. Food and Drug Administration (FDA). This system includes a reader that has been approved as a standalone device. Notably, the glucose sensor used in this system is the smallest, thinnest, and most discreet in the world. Abbott is now focused on expediting the process of getting the FreeStyle Libre 3 system included in Medicare's list of covered systems.
- March 2022: Dexcom released G7 first in the U.K. and will expand the launch across Europe throughout 2022. Meanwhile, the CGM system currently is under review by the Food and Drug Administration for an eventual U.S. release.
North America Diabetes Care Devices Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.3 Market Restraints
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
-
5.1 Product
- 5.1.1 Monitoring Devices
- 5.1.1.1 Self-monitoring Blood Glucose Devices
- 5.1.1.1.1 Glucometer Devices
- 5.1.1.1.2 Blood Glucose Test Strips
- 5.1.1.1.3 Lancets
- 5.1.1.2 Continuous Glucose Monitoring
- 5.1.1.2.1 Sensors
- 5.1.1.2.2 Durables
- 5.1.2 Management Devices
- 5.1.2.1 Insulin Pump
- 5.1.2.1.1 Insulin Pump Device
- 5.1.2.1.2 Insulin Pump Reservoir
- 5.1.2.1.3 Infusion Set
- 5.1.2.2 Insulin Syringes
- 5.1.2.3 Cartridges in Reusable pens
- 5.1.2.4 Insulin Disposable Pens
- 5.1.2.5 Jet Injectors
-
5.2 Geography
- 5.2.1 United States
- 5.2.2 Canada
- 5.2.3 Rest of North America
6. Market Indicators
- 6.1 Type-1 Diabetes Population
- 6.2 Type-2 Diabetes Population
7. COMPETITIVE LANDSCAPE
-
7.1 Company Profiles
- 7.1.1 Becton Dickinson and Company
- 7.1.2 Medtronic
- 7.1.3 F. Hoffmann-La Roche AG
- 7.1.4 Insulet
- 7.1.5 Abbott
- 7.1.6 Dexcom
- 7.1.7 Tandem
- 7.1.8 Ypsomed
- 7.1.9 Novo Nordisk
- 7.1.10 Sanofi
- 7.1.11 Eli Lilly
- *List Not Exhaustive
- 7.2 Company Share Analysis
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
North America Diabetes Care Devices Industry Segmentation
Diabetes patients can monitor and control their blood glucose levels with the use of diabetes equipment. Using diabetes devices can dramatically improve your diabetes status. The North American diabetes care devices market is segmented by monitoring devices, management devices, and geography. The report offers the value (in USD) and Volume (in Units) for the above segments.
| Product | Monitoring Devices | Self-monitoring Blood Glucose Devices | Glucometer Devices |
| Blood Glucose Test Strips | |||
| Lancets | |||
| Product | Monitoring Devices | Continuous Glucose Monitoring | Sensors |
| Durables | |||
| Product | Management Devices | Insulin Pump | Insulin Pump Device |
| Insulin Pump Reservoir | |||
| Infusion Set | |||
| Product | Management Devices | Insulin Syringes | |
| Cartridges in Reusable pens | |||
| Insulin Disposable Pens | |||
| Jet Injectors | |||
| Geography | United States | ||
| Canada | |||
| Rest of North America |
North America Diabetes Care Devices Market Research FAQs
How big is the North America Diabetes Care Devices Market?
The North America Diabetes Care Devices Market size is expected to reach USD 27.52 billion in 2024 and grow at a CAGR of 6.21% to reach USD 37.19 billion by 2029.
What is the current North America Diabetes Care Devices Market size?
In 2024, the North America Diabetes Care Devices Market size is expected to reach USD 27.52 billion.
Who are the key players in North America Diabetes Care Devices Market?
Dexcom, Medtronic, F. Hoffmann-La Roche AG, Novo Nordisk and Becton, Dickinson and Company are the major companies operating in the North America Diabetes Care Devices Market.
What years does this North America Diabetes Care Devices Market cover, and what was the market size in 2023?
In 2023, the North America Diabetes Care Devices Market size was estimated at USD 25.81 billion. The report covers the North America Diabetes Care Devices Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the North America Diabetes Care Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
North America Diabetes Care Devices Industry Report
Statistics for the 2024 North America Diabetes Care Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. North America Diabetes Care Devices analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
